Global Eosinophilic Esophagitis (EoE) Market to Witness Significant Growth Through 2030, Driven by Advancements in Diagnostics and Emerging Biologic Therapies, Reveals DelveInsight

The global Eosinophilic Esophagitis (EoE) market is expected to experience substantial growth during the forecast period 2018–2030, fueled by increasing disease awareness, advancements in diagnostic technologies, rising healthcare expenditure, and ongoing development of targeted biologic therapies. According to DelveInsight’s latest report, the EoE market across the seven major markets (7MM) was valued at approximately USD 430.9 million in 2020 and is anticipated to witness significant transformation over the coming years.

Download the free sample report to explore the Eosinophilic Esophagitis market in detail: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Key Highlights From the Eosinophilic Esophagitis Market Report

The Eosinophilic Esophagitis market is projected to expand steadily through 2030 due to increasing disease prevalence, improved diagnostic capabilities, and the emergence of novel biologic therapeutic approaches aimed at enhancing efficacy and improving patient outcomes.

The market size of Eosinophilic Esophagitis across the 7MM reached approximately USD 430.9 million in 2020 and is expected to grow significantly during the forecast period 2018–2030.

Key companies operating in the Eosinophilic Esophagitis market include Takeda/Shire, Bristol-Myers Squibb, Regeneron Pharmaceuticals/Sanofi, AstraZeneca, Allakos, and Ellodi Pharmaceuticals, among other major therapeutics providers.

The report highlights increasing research efforts focused on improving treatment efficacy, developing targeted biologic therapies, and optimizing treatment algorithms combining diet, drugs, and dilation (“3Ds”).

Ongoing developments in biologic immunotherapies, anti-inflammatory agents, and enhanced diagnostic methodologies are expected to reshape the EoE treatment landscape in the coming years.

Understanding Eosinophilic Esophagitis (EoE)

Eosinophilic Esophagitis (EoE) is a chronic, local immune-mediated esophageal disease clinically and histologically characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. It is a distinct disease entity that was first described in 1978, misinterpreted as achalasia, and formally recognized as a distinct condition more than a decade later.

The disease is characterized by major symptoms including heartburn, regurgitation, esophageal stenosis, and dysphagia, with greater prevalence in young adults and children. Established risk factors include male gender, Caucasian race, and atopy, with genetic predisposition supported by family clustering and specific genetic polymorphisms.

The pathophysiology of EoE is complex, involving a network of various cells and molecules including eosinophils, Th2 cells, thymic stromal lymphopoietin (TSLP), transforming growth factor-beta 1 (TGF-β1), and interleukin-13 (IL-13). Environmental factors, including the timing and nature of food and aeroallergen exposure during immune system development, contribute significantly to disease manifestation.

Access a free sample PDF to explore the EoE therapeutic landscape: Eosinophilic Esophagitis Epidemiology Insights

Eosinophilic Esophagitis (EoE) Epidemiology Insights

The epidemiology section of the report provides detailed historical and forecasted trends of EoE across the seven major markets from 2018 to 2030.

Key epidemiological insights include:

• Total diagnosed prevalent cases of EoE in the 7MM

• Gender-specific diagnosed prevalent cases

• Age-specific diagnosed prevalent cases

• Country-wise epidemiological analysis across the United States, EU5, and Japan

The report enables stakeholders to better understand disease burden, patient demographics, and evolving epidemiological trends supporting strategic planning and commercial decision-making.

The report offers a detailed overview of current diagnostic and treatment practices for EoE: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Diagnosis

Diagnostic approaches covered in the report include:

• Endoscopic evaluation

• Histological examination (requiring ≥15 eosinophils per high-power field for confirmation)

• Identification of endoscopic features (linear grooves, concentric rings, whitish exudates, Schatzki rings)

• Esophageal mucosal biopsy analysis

• Assessment of esophageal narrowing and strictures

Advancements in endoscopic imaging and standardized histological criteria are improving early detection and disease monitoring capabilities.

Treatment

The treatment landscape analysis includes the fundamental “3D” treatment concept:

Dietary Management:

• Empirical food elimination diets

• Guided food elimination based on allergy testing

• Dietary modification to avoid dysphagia and food impaction

Pharmacologic Therapy:

• Proton pump inhibitors (PPIs) as first-line treatment with response rates of 30–70%

• Corticosteroid formulations including budesonide, fluticasone propionate, and ciclesonide

• Immunosuppressive agents

• Novel targeted biologic therapies

Mechanical Intervention:

• Endoscopic bougie dilation

• Balloon dilation for esophageal strictures

• Periodic dilation as acceptable alternative therapy

Regional treatment guidelines and algorithms across the US, Europe, and Japan are provided to support standardized clinical decision-making.

Eosinophilic Esophagitis (EoE) Drug Chapters

The report provides comprehensive analysis of marketed products and emerging pipeline therapies under development for EoE treatment.

Marketed Therapies

The report covers currently available therapies and treatment options utilized in clinical practice for EoE management, including proton pump inhibitors, topical corticosteroids, and endoscopic dilation procedures.

Emerging Therapies

Budesonide Oral Suspension (Takeda/Shire) An oral viscous formulation of budesonide formulated specifically as an investigational treatment for EoE. Clinical trials demonstrate this formulation is more effective than nebulized or swallowed budesonide for improving esophageal eosinophil counts and endoscopic findings in adults. The US FDA has granted priority review, breakthrough therapy designation, and orphan designation. The company submitted a new drug application (NDA) based on pivotal Phase III trials ORBIT1 and ORBIT2, with additional Phase III continuation studies underway for adolescent and adult subjects.

Cendakimab (Bristol-Myers Squibb) A recombinant humanized, high-affinity, selective anti-interleukin-13 (IL-13) monoclonal antibody that binds an IL-13 epitope preventing its binding to both IL-13 receptor subtypes. The drug has been granted orphan drug designation for EoE treatment. Phase II studies demonstrated positive results, and Phase III clinical trials are currently evaluating efficacy and safety in adult and adolescent participants.

The pipeline section also evaluates additional late-stage and mid-stage therapies including:

• Dupilumab (Regeneron Pharmaceuticals/Sanofi)

• APT-1011 (Ellodi Pharmaceuticals)

• Benralizumab (AstraZeneca)

• Lirentelimab (Allakos)

The report further analyzes:

• Clinical trial activities and endpoints

• Pharmacological mechanisms of action

• Licensing and collaboration agreements

• Patent and regulatory developments

• Recent company updates and strategic initiatives

Eosinophilic Esophagitis (EoE) Market Outlook

The Eosinophilic Esophagitis market outlook section delivers detailed insights into current and forecasted market trends by evaluating:

• Existing and emerging therapies

• Unmet clinical needs

• Market drivers and barriers

• Therapy-specific uptake trends

• Competitive positioning of marketed and pipeline products

The report also assesses annual therapy costs, expected launch timelines, patient eligibility criteria, market penetration potential, and key opinion leader perspectives influencing future adoption trends.

According to DelveInsight, the Eosinophilic Esophagitis market across the 7MM is anticipated to undergo significant transformation during the forecast period 2018–2030.

Regional Eosinophilic Esophagitis Market OutlookUnited States Market Outlook

This section provides detailed analysis of the total EoE market size and therapy-specific market trends in the United States. The United States accounts for the highest market size of EoE in comparison to the EU5 countries and Japan. The market analysis includes:

• PPIs as first-line treatment with initial doses of 20–40 mg or 1 mg/kg per dose administered twice daily

• Corticosteroid efficacy in achieving histological remission

• Bougie and balloon dilation as the only endoscopic treatment for persistent dysphagia

• Current and forecasted therapy adoption trends

EU5 Market Outlook

Comprehensive market analysis is provided for Germany, France, Italy, Spain, and the United Kingdom, covering:

• Current and forecasted therapy adoption trends

• Regional variations in treatment approaches

• Market dynamics and competitive landscape

Japan Market Outlook

The report also evaluates the EoE market dynamics and therapy landscape in Japan, providing insights specific to the Japanese healthcare system and treatment practices.

Eosinophilic Esophagitis (EoE) Drugs Uptake and Pipeline Development Activities

The report evaluates the expected uptake of recently launched and upcoming therapies during the study period 2018–2030. The analysis focuses on:

• Patient uptake trends by therapy type

• Therapy adoption rates across regions

• Market share analysis

• Commercial potential of pipeline candidates

• Reasons behind maximal use of new drugs

• Comparison of drugs based on market share and size

Additionally, the report highlights:

• Phase III, Phase II/III, Phase II, and Phase I/II pipeline candidates

• Collaborations and licensing agreements

• Mergers and acquisitions

• Patent activities

• Strategic partnerships influencing market expansion

• Key players involved in developing targeted therapeutics

Reimbursement Scenario in Eosinophilic Esophagitis (EoE)

The report provides valuable reimbursement insights supporting strategic market access planning. It evaluates pricing and reimbursement challenges across key geographies while identifying commercially attractive markets with lower reimbursement barriers and favorable payer policies.

KOL Views and Competitive Intelligence Analysis

To validate secondary research findings and assess evolving treatment trends, DelveInsight incorporates perspectives from key opinion leaders (KOLs) and subject matter experts working in the EoE domain. These insights support understanding of current and emerging therapy treatment patterns and market trends.

The report also includes extensive competitive intelligence analysis utilizing tools such as:

• SWOT Analysis

• PESTLE Analysis

• Porter’s Five Forces

• BCG Matrix

• Market Entry Strategies

These insights support stakeholders in identifying future opportunities and competitive positioning within the evolving market landscape.

Eosinophilic Esophagitis (EoE) Market Drivers and ChallengesKey Market Drivers

• Increasing awareness and diagnosis of EoE

• Rising prevalence of immune-mediated esophageal disorders

• Advancements in endoscopic diagnostics and standardized histological criteria

• Growing healthcare expenditure globally

• Unmet clinical need for FDA-approved targeted therapies

• Emerging biologic therapies offering improved efficacy

• Rising incidence in young adults and children

• Increasing research into improved treatment algorithms

Key Market Challenges

• Lack of FDA-approved drugs specifically for EoE treatment

• Variability in treatment response and disease natural history

• Complexity of the “3D” treatment approach requiring multidisciplinary management

• Limited uniform endpoints in clinical trials

• Recurrence and relapse risks requiring long-term maintenance therapy

• Need for deeper understanding of disease progression

• Reimbursement and pricing challenges for emerging biologic therapies

• Regional variations in treatment guidelines and practices

Download sample report now – https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Eosinophilic Esophagitis (EoE) Report Scope

The report offers global coverage with focus on:

• Historical and forecasted market trends from 2018 to 2030

• Epidemiology analysis across the 7MM

• Current and emerging therapies

• Competitive landscape and pipeline assessment

• Market drivers, barriers, and unmet needs

• Strategic insights for stakeholders and healthcare companies

• Detailed disease understanding and treatment algorithms

• Comprehensive KOL perspectives and competitive intelligence

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions to improve business performance and strategic decision-making.

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/